Search Within

Carl Ola Landgren

Formats
  1. Meeting Abstract (155)
  2. Journal Article (151)
  3. Review (14)
  4. Research Letter (7)
  5. Book Section (3)
  6. Correspondence (2)
  7. Guidelines (2)
  8. Conference Paper (1)
  9. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (336)
  2. Department of Medicine (336)
  3. Hematologic Malignancies Research (336)
  4. Hematologic Malignancies, Division of (336)
  5. Myeloma (336)
  6. Survivorship Research (132)

More Groups

People
  1. Neha Korde (106)
  2. Sham Mailankody (91)
  3. Alexander Lesokhin (83)
  4. Malin Hultcrantz (81)
  5. Hani Hassoun (77)
  6. Sergio Giralt (73)

More People

Years
  1. 2023 (2)
  2. 2022 (4)
  3. 2021 (21)
  4. 2020 (52)
  5. 2019 (56)
  6. 2018 (51)

More Years

Publications
  1. Blood (102)
  2. Haematologica (25)
  3. Clinical Lymphoma, Myeloma and Leukemia (21)
  4. Leukemia and Lymphoma (16)
  5. Biology of Blood and Marrow Transplantation (13)
  6. Blood Cancer Journal (10)

More Publications

Publishers
  1. American Society of Hematology (109)
  2. Elsevier Inc. (45)
  3. Nature Publishing Group (29)
  4. Ferrata Storti Foundation (25)
  5. Taylor & Francis Group (17)
  6. American Association for Cancer Research (15)

More Publishers

Results (336)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sustained high rates of complete response and minimal residual disease negativity after 8 cycles of carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R) in patients with high-risk smoldering multiple myeloma: Updated results of clinical and correlative phase 2 study
    Meeting Abstract

    Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Comparison of standard assays (serum immunofixation and protein electrophoresis) with Hevylite assay in patients with multiple myeloma
    Meeting Abstract

    Hassoun, H.; Ruiz, R.; Kazunori, M.; Azzi, K.; Devlin, S.; Cooper, B.; Lendvai, N.; Landau, H.; Lesokhin, A. M.; Chung, D. J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy
    Meeting Abstract

    Hassoun, H.; Roshal, M.; Sabari, J.; Cooper, B.; Nguyen, J.; Ruiz, R.; Gao, Q.; Landau, H.; Lendvai, N.; Chung, D. J.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • A phase 1b study investigating carfilzomib administered once weekly in combination with lenalidomide and dexamethasone in patients with multiple myeloma
    Meeting Abstract

    Biran, N.; Siegel, D. S.; Berdeja, J. G.; Faber, E.; Seneviratne, L.; Alsina, M.; Bensinger, W.; Kimball, A. S.; Zhou, K.; Landgren, O.
    Blood (2016)

    Fulltext@MSK | Save
  • Bloodstream infections in patients with chronic lymphocytic leukemia: A longitudinal single-center study
    Journal Article

    Kjellander, C.; Björkholm, M.; Källman, O.; Giske, C. G.; Weibull, C. E.; Löve, T. J.; Landgren, O.; Kristinsson, S. Y.
    Annals of Hematology (2016)

    Fulltext@MSK | Save
  • Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
    Journal Article

    Landgren, O.; Owen, R. G.
    Cytometry Part B—Clinical Cytometry (2016)

    Fulltext@MSK | Save
  • A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival
    Journal Article

    Kazandjian, D.; Landgren, O.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status
    Journal Article

    Landgren, O.
    Seminars in Oncology (2016)

    Fulltext@MSK | Save
  • Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis
    Journal Article

    Landgren, O.; Devlin, S.; Boulad, M.; Mailankody, S.
    Bone Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
    Journal Article

    Kumar, S.; Paiva, B.; Anderson, K. C.; Durie, B.; Landgren, O.; Moreau, P.; Munshi, N.; Lonial, S.; Bladé, J.; Mateos, M. V.; more...
    Lancet Oncology (2016)

    Fulltext@MSK | Save